Tildrakizumab
ApprovedTerminated 0 watching 0 views this week🔥 Hot
80
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Plaque Psoriasis
Conditions
Plaque Psoriasis
Trial Timeline
Jan 29, 2020 → Jul 31, 2020
NCT ID
NCT04339595About Tildrakizumab
Tildrakizumab is a approved stage product being developed by Almirall for Plaque Psoriasis. The current trial status is terminated. This product is registered under clinical trial identifier NCT04339595. Target conditions include Plaque Psoriasis.
Hype Score Breakdown
Clinical
30
Activity
20
Company
5
Novelty
10
Community
12
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06488170 | Pre-clinical | Active |
| NCT06029257 | Pre-clinical | Recruiting |
| NCT06030076 | Pre-clinical | Recruiting |
| NCT04823247 | Pre-clinical | Completed |
| NCT04339595 | Approved | Terminated |
| NCT04203693 | Pre-clinical | Completed |
Competing Products
20 competing products in Plaque Psoriasis